Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Pfizer Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while Pfizer Inc trades at $28.18 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 418.6× JPMorgan Diversified Return International Eqty ETF's market cap, and Pfizer Inc pays a 6.18% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Pfizer Inc for 158 Days on average.
| JPIN | PFE | |
|---|---|---|
Market Cap | $378.77M | $158.56B |
Volume | 13,861 | 44,138,282 |
52-Week High | $77.80 | $29.02 |
52-Week Low | $64.96 | $23.67 |
Typical Hold Time | 120 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.01, showing minimal daily movement with a 0.1% gain. Technical indicators are predominantly bearish, with moving averages and oscillators signaling selling pressure, though RSI levels suggest potential oversold conditions. The ETF, designed for international equity exposure, lacks current fundamental data for valuation ratios and profitability metrics.
The outlook remains cautious due to strong bearish technical signals and absence of recent financial updates. Key risks include market volatility and reliance on international equities. Investors should await earnings reports for fundamental clarity, as current data is insufficient to assess valuation or growth prospects.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
